178 related articles for article (PubMed ID: 2720647)
21. [Platinum concentrations in human tissue after administration of cisplatin].
Tochigi T; Ono K; Yoshikawa K; Hoshi S; Orikasa S; Imai Y
Gan To Kagaku Ryoho; 1988 Feb; 15(2):269-75. PubMed ID: 3341789
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
[TBL] [Abstract][Full Text] [Related]
24. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
25. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
26. Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques.
Fichtinger-Schepman AM; Dijt FJ; Bedford P; van Oosterom AT; Hill BT; Berends F
IARC Sci Publ; 1988; (89):321-8. PubMed ID: 3198216
[TBL] [Abstract][Full Text] [Related]
27. [An autopsy case of rectal cancer receiving cisplatin at total dose of 3.250 mg and platinum concentrations in autopsy tissue samples].
Ishigaki H; Satoh S; Saitoh S; Yoshida Y; Ebina T; Satoh T; Nara K; Asano M; Oh-ishi S; Satoh F
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3805-8. PubMed ID: 2596863
[TBL] [Abstract][Full Text] [Related]
28. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity.
McDonald ES; Randon KR; Knight A; Windebank AJ
Neurobiol Dis; 2005 Mar; 18(2):305-13. PubMed ID: 15686959
[TBL] [Abstract][Full Text] [Related]
30. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans.
Wild CP; Hasegawa R; Barraud L; Chutimataewin S; Chapot B; Ito N; Montesano R
Cancer Epidemiol Biomarkers Prev; 1996 Mar; 5(3):179-89. PubMed ID: 8833618
[TBL] [Abstract][Full Text] [Related]
31. Analysis of DNA adducts in putative premalignant hepatic nodules and nontarget tissues of rats during 2-acetylaminofluorene carcinogenesis.
Gupta RC; Earley K; Becker FF
Cancer Res; 1988 Sep; 48(18):5270-4. PubMed ID: 3409250
[TBL] [Abstract][Full Text] [Related]
32. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin-DNA adduct determination in the hepatic albumin gene as compared to whole genomic DNA.
Zhang Z; Poirier MC
Chem Res Toxicol; 1997 Sep; 10(9):971-7. PubMed ID: 9305578
[TBL] [Abstract][Full Text] [Related]
34. Collagen chemoembolization: pharmacokinetics and tissue tolerance of cis-diamminedichloroplatinum(II) in porcine liver and rabbit kidney.
Daniels JR; Sternlicht M; Daniels AM
Cancer Res; 1988 May; 48(9):2446-50. PubMed ID: 3356008
[TBL] [Abstract][Full Text] [Related]
35. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
Gupta-Burt S; Shamkhani H; Reed E; Tarone RE; Allegra CJ; Pai LH; Poirier MC
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875
[TBL] [Abstract][Full Text] [Related]
36. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
Darcy KM; Tian C; Reed E
Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
[TBL] [Abstract][Full Text] [Related]
37. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
Ognio E; Chiavarina B; Caviglioli G; Lapide M; Viale M
Arch Toxicol; 2004 Oct; 78(10):584-8. PubMed ID: 15150682
[TBL] [Abstract][Full Text] [Related]
38. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
39. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
Poirier MC; Egorin MJ; Fichtinger-Schepman AM; Yuspa SH; Reed E
IARC Sci Publ; 1988; (89):313-20. PubMed ID: 3058599
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Hoebers FJ; Pluim D; Hart AA; Verheij M; Balm AJ; Fons G; Rasch CR; Schellens JH; Stalpers LJ; Bartelink H; Begg AC
Cancer Chemother Pharmacol; 2008 May; 61(6):1075-81. PubMed ID: 17639394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
